化学
鉴定(生物学)
激酶
细胞生物学
MAP激酶激酶激酶
蛋白激酶A
癌症研究
生物化学
对偶(语法数字)
分子生物学
酶抑制剂
细胞培养
酶
谱系(遗传)
下调和上调
细胞周期蛋白依赖激酶2
信号转导
细胞周期蛋白依赖激酶4
体外
细胞周期蛋白依赖激酶9
丝裂原活化蛋白激酶
蛋白激酶R
丝裂原活化蛋白激酶激酶
人体乳房
作者
Velma Ganga Reddy,Sandeep Kumar,Piush Srivastava,Sweta Misra,Rakesh Sathish Nair,Soumya Reddy Musku,Martha S Ackerman-Berrier,Sunil Kumar Singh,Harsh Vyas,Erick T. M. Alves,Basabi Rana,Rui Xiong,Laura J. Bloem,Ajay Rana,Gregory R. J. Thatcher
标识
DOI:10.1021/acs.jmedchem.5c03558
摘要
Triple-negative breast cancer (TNBC) is aggressive and lacks targeted therapeutic options. Mixed lineage kinase 3 (MLK3) plays a key role in TNBC progression. To enhance the therapeutic impact of MLK3 inhibition in TNBC, a novel MLK3 inhibitor scaffold was optimized to incorporate inhibition of NAMPT, often upregulated in TNBC to meet the increased demand for NAD + . Cell-free and cell-based assays for MLK3 and NAMPT inhibition drove the design and optimization of GR2–128, a dual inhibitor with matched nanomolar inhibition for MLK3 and NAMPT, antiproliferative in TNBC cell lines, with acceptable metabolic stability and bioavailability. GR2–128 attenuated tumorigenesis in a syngeneic mouse breast cancer model, increasing apoptosis via inhibition of MLK3 and NAMPT, attenuating macrophage and neutrophil infiltration and increasing tumor T-cell markers without change in B-cell count. These data support the dual inhibition of MLK3/NAMPT as a therapeutic approach to TNBC, with the potential for tumor immuno-sensitization.
科研通智能强力驱动
Strongly Powered by AbleSci AI